These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 29241782)

  • 1. A novel treatment for limited mouth opening due to facial fibrosis: A case series.
    Hoverson K; Love T; Lam TK; Marquart JD
    J Am Acad Dermatol; 2018 Jan; 78(1):190-192. PubMed ID: 29241782
    [No Abstract]   [Full Text] [Related]  

  • 2. Oro-facial fibrosis in systemic sclerosis: a reconstructive journey.
    Jeon FHK; Griffin M; Varghese J; Butler PEM
    BMJ Case Rep; 2020 Oct; 13(10):. PubMed ID: 33040038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Somatosensory input and oromandibular dystonia.
    Møller E; Bakke M; Dalager T; Werdelin LM; Lonsdale MN; Højgaard L; Friberg L
    Clin Neurol Neurosurg; 2013 Jul; 115(7):1141-3. PubMed ID: 23036658
    [No Abstract]   [Full Text] [Related]  

  • 4. [Mouth opening in patients with systemic sclerosis: base analysis and during follow-up].
    Tanturri De Horatio C; Tirri E; Valletta R; Tirri G; Rengo S
    Minerva Stomatol; 2000 Sep; 49(9):409-13. PubMed ID: 11256201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of facial and orolinguomandibular tardive dystonia by botulinum toxin A: evidence of a long-lasting effect.
    Kañovský P; Streitová H; Bares M; Hortová H
    Mov Disord; 1999 Sep; 14(5):886-8. PubMed ID: 10495063
    [No Abstract]   [Full Text] [Related]  

  • 6. Ischaemic ulcers on the toes secondary to Raynaud phenomenon in a patient with systemic sclerosis successfully treated with botulinum toxin.
    Garrido-Ríos AA; González-Olivares M; Navarro-Vidal B; Martínez-Morán C; Borbujo J
    Clin Exp Dermatol; 2018 Jun; 43(4):503-505. PubMed ID: 29274125
    [No Abstract]   [Full Text] [Related]  

  • 7. [Marked effect of botulinum toxin A for severe toe digital ulcers in a patient with systemic sclerosis].
    Nielsen JB; Hvid L; Olesen AB
    Ugeskr Laeger; 2014 Feb; 176(8A):V08130527. PubMed ID: 25350310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective study of the use of botulinum toxin injections in the treatment of Raynaud's syndrome associated with scleroderma.
    Uppal L; Dhaliwal K; Butler PE
    J Hand Surg Eur Vol; 2014 Oct; 39(8):876-80. PubMed ID: 24369360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized Split-Face Study to Assess the Efficacy and Safety of AbobotulinumtoxinA Versus OnabotulinumtoxinA in the Treatment of Melomental Folds (Depressor Anguli Oris).
    Fabi SG; Massaki AN; Guiha I; Goldman MP
    Dermatol Surg; 2015 Nov; 41(11):1323-5. PubMed ID: 26506065
    [No Abstract]   [Full Text] [Related]  

  • 10. The spectrum of orofacial manifestations in systemic sclerosis: a challenging management.
    Jung S; Martin T; Schmittbuhl M; Huck O
    Oral Dis; 2017 May; 23(4):424-439. PubMed ID: 27196369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation and treatment of synkinesis with botulinum toxin following facial nerve palsy.
    Toffola ED; Furini F; Redaelli C; Prestifilippo E; Bejor M
    Disabil Rehabil; 2010; 32(17):1414-8. PubMed ID: 20156046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Botulinum toxin type A contribution in the treatment of Raynaud's phenomenon due to systemic sclerosis].
    Serri J; Legré R; Veit V; Guardia C; Gay AM
    Ann Chir Plast Esthet; 2013 Dec; 58(6):658-62. PubMed ID: 22204894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Botulinum toxin and facial palsy. Our experience].
    Navarrete Alvaro ML; Junyent J; Torrent L
    Acta Otorrinolaringol Esp; 2010; 61(4):277-81. PubMed ID: 20400055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Botulinum toxin type A vs type B for axillary hyperhidrosis in a case series of patients observed for 6 months.
    Frasson E; Brigo F; Acler M; Didonè G; Vicentini S; Bertolasi L
    Arch Dermatol; 2011 Jan; 147(1):122-3. PubMed ID: 21242408
    [No Abstract]   [Full Text] [Related]  

  • 15. Botulinum toxin-responsive oromandibular dystonia in cerebrotendinous xanthomatosis.
    Posada IJ; Ramos A
    Parkinsonism Relat Disord; 2011 Aug; 17(7):570-2. PubMed ID: 21531161
    [No Abstract]   [Full Text] [Related]  

  • 16. Botulinum toxin-induced immobilization of lower facial wounds.
    Gassner HG; Sherris DA; Friedman O
    Arch Facial Plast Surg; 2009; 11(2):140-2. PubMed ID: 19289689
    [No Abstract]   [Full Text] [Related]  

  • 17. Treatment of facial myokymia in multiple sclerosis with botulinum toxin.
    Habek M; Adamec I; Gabelić T; Brinar VV
    Acta Neurol Belg; 2012 Dec; 112(4):423-4. PubMed ID: 22669610
    [No Abstract]   [Full Text] [Related]  

  • 18. Surgical correction of microstomia in a patient with scleroderma.
    TerzIoğlu A; Ciğşar B; Aslan G
    Ann Plast Surg; 2002 Aug; 49(2):222-3. PubMed ID: 12187361
    [No Abstract]   [Full Text] [Related]  

  • 19. Improvement of "En Coup de Sabre" Morphea and Associated Headaches With Botulinum Toxin Injections.
    Rimoin L; Arbiser J
    Dermatol Surg; 2016 Oct; 42(10):1216-9. PubMed ID: 27465255
    [No Abstract]   [Full Text] [Related]  

  • 20. Botulinum toxin for treatment of jaw opening dystonia in Hallervorden-Spatz syndrome.
    Dressler D; Wittstock M; Benecke R
    Eur Neurol; 2001; 45(4):287-8. PubMed ID: 11385272
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.